13F Holdings
中文EN

NTLA Intellia Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1652130 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.1%
TTM net income YoY4.4%
TTM EPS YoY21.2%
Revenue 3-yr CAGR77.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-821.2%
Net margin-805.7%
FCF margin-677.1%
EBITDA margin-805.0%

Returns

ROE-62.6%
ROA-46.6%
ROIC (approx.)-63.2%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets32.1%
Debt / equity0.12x
Current ratio6.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$67.67M$57.88M$6.60M$11.40M$2.90M
Cost of revenue————$0
Gross profit————$2.90M
R&D expense$388.86M$466.31M$435.07M$419.98M$229.81M
SG&A expense$119.80M$125.83M$116.50M$90.31M$71.10M
Operating income-$440.99M-$534.26M-$515.29M-$458.16M-$267.85M
Income tax$0————
Net income-$412.69M-$519.02M-$481.19M-$474.19M-$267.89M
EBITDA-$431.22M-$523.98M-$506.31M-$450.59M-$260.96M
EPS (basic)-3.81-5.25-5.42-6.16-3.78
EPS (diluted)-3.81-5.25-5.42-6.16-3.78
Weighted avg. shares (diluted)108.38M98.85M88.77M76.97M70.89M
Balance sheet
Cash & equivalents$155.46M$189.18M$226.75M$523.51M$123.41M
Short-term investments$294.42M$412.33M$685.48M$669.12M$625.28M
Receivables$9.47M$8.52M$36.46M$3.77M$2.03M
Current assets$527.71M$639.86M$998.33M$1.22B$769.30M
PP&E, net$17.67M$27.38M$32.76M$27.92M$20.97M
Total assets$842.13M$1.19B$1.30B$1.52B$1.29B
Current liabilities$103.88M$110.85M$115.21M$126.55M$125.83M
Long-term debt$0————
Total debt$0————
Total liabilities$170.73M$319.06M$250.81M$284.53M$254.22M
Shareholders' equity$671.39M$871.96M$1.05B$1.24B$1.04B
Net debt-$155.46M————
Shares outstanding116.32M102.03M93.00M87.10M74.49M
Cash flow statement
Operating cash flow-$394.74M-$348.88M-$394.09M-$333.29M-$225.03M
Capital expenditure$1.13M$5.78M$13.98M$13.56M$12.76M
Free cash flow-$395.87M-$354.66M-$408.07M-$346.85M-$237.79M
Investing cash flow$228.03M$125.57M-$31.35M$160.31M-$550.78M
Financing cash flow$131.49M$185.75M$130.32M$582.96M$736.69M
Depreciation & amortization$9.77M$10.29M$8.98M$7.57M$6.89M
Stock-based compensation$80.22M$154.27M$134.05M$91.40M$47.01M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.